Blog
A biotech VC’s prescription for what ails pharma
How can we balance innovation and affordability in prescription drugs? Peter Kolchinsky has some ideas.
The cost-benefit revolution is far from over
In his new book, Cass Sunstein explores how to bring analytic rigor to policy decisions.
Can Businesses Learn 'Superforecasting'? Easier Said Than Done
Business leaders should read Philip Tetlock's new book on analyzing data to predict the future - but whether they'll be able to implement its ideas is far from certain.
Technology, end-of-life care, and 'Being Mortal'
Atul Gawande's recent book on end-of-life care is inspiring and thought-provoking - and an important must-read for tech experts, entrepreneurs, and investors.
From bedside to bench and back again: Review of “Cured” by Nathalia Holt
In HIV and many other areas of biopharma, there are no shortcuts - sometimes science progresses a single patient at a time.
Baby biotech grows up: Review of "The Antidote" by Barry Werth
How do you build a drug company? Barry Werth continues the story of Vertex's birth and teenage years that he started with "Billion Dollar Molecule".
A victim of his success: Malcolm Gladwell's "David and Goliath"
Let's get one thing out of the way: if you're a Gladwell hater, this book will not change your mind.
The Mystery of McKinsey: Review of "The Firm" by Duff McDonald
Almost 100 years since its founding, we're still no closer to answering the age-old question about McKinsey: Are they worth it?
How to cure cancer? A review of "The Truth in Small Doses" by Clifton Leaf
Leaf's book is a powerful call to action to focus on the "C" word in oncology - "cure".